O
10.10
-1.38 (-12.02%)
| Previous Close | 11.48 |
| Open | 11.43 |
| Volume | 614,907 |
| Avg. Volume (3M) | 466,853 |
| Market Cap | 578,707,776 |
| Price / Book | 2.64 |
| 52 Weeks Range | |
| Earnings Date | 15 Nov 2024 - 21 Nov 2024 |
| Diluted EPS (TTM) | -2.28 |
| Total Debt/Equity (MRQ) | 0.28% |
| Current Ratio (MRQ) | 7.00 |
| Operating Cash Flow (TTM) | -92.27 M |
| Levered Free Cash Flow (TTM) | -44.97 M |
| Return on Assets (TTM) | -32.48% |
| Return on Equity (TTM) | -51.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Olema Pharmaceuticals, Inc. | Bearish | Bullish |
Stockmoo Score
0.4
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.38 |
|
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 3.63% |
| % Held by Institutions | 106.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Candriam S.C.A. | 30 Jun 2024 | 1,058,673 |
| 52 Weeks Range | ||
| Median | 30.00 (197.03%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Nov 2024 | 30.00 (197.03%) | Buy | 11.48 |
| 24 Oct 2024 | 30.00 (197.03%) | Buy | 11.72 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |